INTERGROUP COALITION AGAINST SARCOMAS (ICAS) • SCIENTIFIC STEERING COMMITTEE : EC Borden, G Demetri, M von Mehren, K Albritton, P Pisters • BIOSTATISTICS : C Rankin, J Crowley • OPERATIONS : G Goetz (SWOG) A COMMITTEE FOCUSED ON INTERGROUP A COMMITTEE FOCUSED ON INTERGROUP DEVELOPMENT OF NEW SARCOMA THERAPEUTICS DEVELOPMENT OF NEW SARCOMA THERAPEUTICS CALGB ECOG NCIC SWOG CALGB ECOG NCIC SWOG Collaborations with COG and ACOSOG Communication with SARC and RTOG
22
Embed
INTERGROUP COALITION AGAINST SARCOMAS (ICAS) SCIENTIFIC STEERING COMMITTEE: EC Borden, G Demetri, M von Mehren, K Albritton, P Pisters BIOSTATISTICS: C.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
INTERGROUP COALITION AGAINST SARCOMAS (ICAS)
• SCIENTIFIC STEERING COMMITTEE: EC Borden, G Demetri, M von Mehren, K Albritton, P Pisters
• BIOSTATISTICS: C Rankin, J Crowley• OPERATIONS: G Goetz (SWOG)
A COMMITTEE FOCUSED ON INTERGROUP A COMMITTEE FOCUSED ON INTERGROUP
DEVELOPMENT OF NEW SARCOMA THERAPEUTICSDEVELOPMENT OF NEW SARCOMA THERAPEUTICS
CALGB ECOG NCIC SWOG CALGB ECOG NCIC SWOG
Collaborations with COG and ACOSOGCommunication with SARC and RTOG
2001-20062001-2006INTERGROUP COALITION AGAINST SARCOMASINTERGROUP COALITION AGAINST SARCOMAS
Goals and Hypotheses • Sharpen definition of histologic subtypes to improve
therapeutic outcomes and prognosis– Hypothesis: Molecular pathology will better define subtypes and thus improve
clinical management and outcomes
• Emphasize targeted therapeutics– Hypothesis: Signal transduction modulators will be effective and histology
specific
• Facilitate intergroup collaborations– Hypothesis: Increased intergroup collaboration will stimulate sarcoma research
Euramos 1 Phase 3 TrialEuropean and American Osteosarcoma Study Group
• Collaborators: COG German Austrian Swiss (COSS) European (EOI) Scandinavian (SSG) Trial Mgmt Group Chair M Bernstein Montreal COG
• Objectives: Improve EFS – Will IE when added to MAP for poor histological responders?– Will PEG-IFN when added to MAP for good histological responders?
• Eligibility– Resectable axial or extremity osteosarcoma– <40
• Registration2 cycles MAPsurgery path reveiw Random MAPx2 MAPx2 MPx2PEG-IFNx2y or IEx3– n=1400– 10% improvement in EFS
INTERGROUP COALITION AGAINST SARCOMAS (ICAS)Ernest C. Borden Chair•